Fludarabine Plus Epirubicin in Untreated or Minimal Pretreated Patients with Chronic Lymphocytic Leukemia – Preliminary Results of a Phase-ll Study

M. J. Rummel,M Schenk,C. Renner,A. Knuth,K. Josten,U. Reinhardt,B. Rendenbach,H.-J. Pielken,C. Wojatschek,Eva Lengfelder,P.S. Mitrou,Dieter Hoelzer,L. Bergmann

Fludarabine Plus Epirubicin in Untreated or Minimal Pretreated Patients with Chronic Lymphocytic Leukemia – Preliminary Results of a Phase-ll Study

1997

M. J. Rummel
M Schenk
C. Renner
A. Knuth
K. Josten
U. Reinhardt
B. Rendenbach
H.-J. Pielken
C. Wojatschek
Eva Lengfelder
P.S. Mitrou
Dieter Hoelzer
L. Bergmann

Background: Fludarabine has been reported to be the most effective single agent in previously treated chronic lymphocytic leukemia (CLL). Based on in vitro synergism of fludarabine

Keywords:

Chronic lymphocytic leukemia
General surgery
Cancer research
Progression-free survival
Virology
Epirubicin
Fludarabine
Medicine
In vitro
single agent
previously treated
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations